IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, has announced a non-exclusive license agreement with Quest Diagnostics Incorporated, a provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests. Additional terms were not disclosed.